Jennison Associates
AIMT

Jennison Associates’s Aimmune Therapeutics AIMT Stock Holding History

Jennison Associates’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-388,458
Closed -$9.29M – 710
2018
Q4 		$9.29M Sell
388,458
-44,518
-10% -$1.15M 0.01% 442
2018
Q3 		$11.8M Buy
432,976
+3,442
+0.8% +$97.4K 0.01% 456
2018
Q2 		$11.6M Buy
429,534
+7,668
+2% +$235K 0.01% 458
2018
Q1 		$13.4M Buy
+421,866
New +$14.8M 0.01% 436
2015
Q4 		– Sell
-200,503
Closed -$5.08M – 762
2015
Q3 		$5.08M Buy
+200,503
New +$4.69M 0.01% 541

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return